Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice

Journal of Pharmaceutical Sciences

Volumn 105, Issue 5, 2016, Pages 1693-1704

  Kijanka, Grzegorz ^a   Bee, Jared S ^b   Bishop, Steven M ^b   Que, Ivo ^c   Löwik, Clemens ^c   Jiskoot, Wim ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b MEDIMMUNE   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

IgG antibody; imaging methods; monoclonal antibody; protein aggregation; proteins

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; OLIGOMER; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRIFUGATION; CONTROLLED STUDY; FLUORESCENCE; FLUORESCENCE IMAGING; GEL PERMEATION CHROMATOGRAPHY; MOUSE; NONHUMAN; PROTEIN AGGREGATION; ANIMAL; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY; PILOT STUDY; PROCEDURES; SIZE EXCLUSION CHROMATOGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, GEL; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MICE; NANOPARTICLES; PILOT PROJECTS; TISSUE DISTRIBUTION;

EID: 84964461820     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2016.02.034     Document Type: Article

References (36)

1. W. Wang, E.Q. Wang, and J.P. Balthasar Monoclonal antibody pharmacokinetics and pharmacodynamics Clin Pharmacol Ther 84 2008 548 558
2. S. Goswami, W. Wang, T. Arakawa, and S. Ohtake Developments and challenges for mAb-based therapeutics Antibodies 2 2013 452 500
3. A.C. Chan, and P.J. Carter Therapeutic antibodies for autoimmunity and inflammation Nat Rev Immunol 10 2010 301 316
4. M.H. Weisman, L.W. Moreland, D.E. Furst, and et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study Clin Ther 25 2003 1700 1721
5. I. Ordás, D.R. Mould, B.G. Feagan, and W.J. Sandborn Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms Clin Pharmacol Ther 91 2012 635 646
6. T.M. Allen Ligand-targeted therapeutics in anticancer therapy Nat Rev Cancer 2 2002 750 763
7. B. Ballou, G.W. Fisher, T.R. Hakala, and D.L. Farkas Tumor detection and visualization using cyanine fluorochrome-labeled antibodies Biotechnol Prog 13 1997 649 658
8. P.A. Van Schouwenburg, L.A. van de Stadt, R.N. de Jong, and et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation Ann Rheum Dis 72 2013 104 109
9. G.M. Bartelds, C.A. Wijbrandts, M.T. Nurmohamed, and et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis Ann Rheum Dis 66 2007 921 926
10. S. Ben-Horin, and Y. Chowers Review article: loss of response to anti-TNF treatments in Crohn's disease Aliment Pharmacol Ther 33 2011 987 995
11. W.Y.K. Hwang, and J. Foote Immunogenicity of engineered antibodies Methods 36 2005 3 10
12. F.A. Harding, M.M. Stickler, J. Razo, and R.B. DuBridge The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions MAbs 2 2010 256 265
13. S. Hermeling, H. Schellekens, C. Maas, M.F. Gebbink, D.J.A. Crommelin, and W. Jiskoot Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation J Pharm Sci 95 2006 1084 1096
14. D. Levêque, S. Wisniewski, and F. Jehl Pharmacokinetics of therapeutic monoclonal antibodies used in oncology Anticancer Res 25 2005 2327 2343
15. A.M. Fathallah, R.B. Bankert, and S.V. Balu-Iyer Immunogenicity of subcutaneously administered therapeutic proteins - a mechanistic perspective AAPS J 15 2013 897 900
16. H.M. Kinnunen, and R.J. Mrsny Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site J Control Release 182 2014 22 32
17. Y.S. Lin, C. Nguyen, J. Mendoza, and et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor J Pharmacol Exp Ther 288 1999 371 378
18. L. Kagan, M.R. Turner, S.V. Balu-Iyer, and D.E. Mager Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats Pharm Res 29 2012 490 499
19. W.F. Richter, S.G. Bhansali, and M.E. Morris Mechanistic determinants of biotherapeutics absorption following SC administration AAPS J 14 2012 559 570
20. EMEA/CHMP/BMWP/14327/2006 Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins 2008 Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003946.pdf Accessed March 23, 2016
21. H. Schellekens Immunogenicity of therapeutic proteins: clinical implications and future prospects Clin Ther 24 2002 1720 1740 [discussion: 1719]
22. H. Schellekens Factors influencing the immunogenicity of therapeutic proteins Nephrol Dial Transplant 20 Suppl 6) 2005 vi3 vi9
23. M. Christie, R.M. Torres, R.M. Kedl, T.W. Randolph, and J.F. Carpenter Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration J Pharm Sci 103 2014 128 139
24. G. Kijanka, W. Jiskoot, H. Schellekens, and V. Brinks Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice Pharm Res 30 2013 1553 1560
25. G. Kijanka, M. Prokopowicz, H. Schellekens, and V. Brinks Influence of aggregation and route of injection on the biodistribution of mouse serum albumin PLoS One 9 2014 e85281
26. V. Filipe, I. Que, J.F. Carpenter, C. Löwik, and W. Jiskoot In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice Pharm Res 31 2014 216 227
27. J.G. Barnard, S. Singh, T.W. Randolph, and J.F. Carpenter Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway J Pharm Sci 100 2011 492 503
28. S. Oliveira, G.A. Van Dongen, M. Stigter-Van Walsum, and et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody Mol Imaging 11 2012 33 46
29. C. Kalonia, O.S. Kumru, I. Prajapati, and et al. Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data J Pharm Sci 104 2015 536 547
30. A.S. Rosenberg, and A.S. Worobec A risk-based approach to immunogenicity concerns of therapeutic protein products: part 2. Considering host-specific and product-specific factors impacting immunogenicity Biopharm Int 17 2004 34 42
31. A.J. Freitag, M. Shomali, S. Michalakis, and et al. Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice Pharm Res 32 2015 430 444
32. J. Bessa, S. Boeckle, H. Beck, and et al. The immunogenicity of antibody aggregates in a novel transgenic mouse model Pharm Res 32 2015 2344 2359
33. Z. Xu, Q. Wang, Y. Zhuang, and et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects J Clin Pharmacol 50 2010 276 284
34. T. Laursen, J. Møller, J.O. Jørgensen, H. Orskov, and J.S. Christiansen Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients Clin Endocrinol (Oxf) 45 1996 333 339
35. S.A. Charman, A.M. Segrave, G.A. Edwards, and C.J.H. Porter Systemic availability and lymphatic transport of human growth hormone administered by subcutaneous injection J Pharm Sci 89 2000 168 177
36. L. Kagan, P. Gershkovich, A. Mendelman, S. Amsili, N. Ezov, and A. Hoffman The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model Eur J Pharm Biopharm 67 2007 759 765